Lymecycline is a second-generation, broad-spectrum tetracycline antibiotic used to treat acne and other susceptible bacterial infections. Some of these infections include upper respiratory tract infections, urinary tract infections, bronchitis, chlamydial infections, and rickettsial infections.
Effect
Pharmacodynamics
Lymecycline binds to the so-called 30S ribosomal subunit and thus prevents aminoacyl-tRNA from binding to the ribosome, which prevents the elongation of polypeptide chains (proteins). This leads to a bacteriostatic effect and thus inhibits the multiplication of pathogens.
Pharmacokinetics
Lymecycline is 77-88% absorbed after oral administration with a relative bioavailability of 70%. Lymecycline is excreted 25% in the urine. The half-life of lymecycline is approximately 8 hours.
Aktories, Förstermann, Hofmann, Starke: Allgemeine und spezielle Pharmakologie und Toxikologie, Elsvier, 2017
Editorial principles
All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Markus Falkenstätter, BSc Author
Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.
Mag. pharm. Stefanie Lehenauer Lector
Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.
The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.
